Johnson & Johnson (NYSE:JNJ) shares rose 0.1%

Shares of Johnson & Johnson ( NYSE:JNJ – Get Free Report ) rose 0.1% on Friday. The company traded as high as $165.00 and last traded at $164.37. About 1,041,066 shares were traded during trading, down 86% from the average daily volume of 7,233,090 shares. Shares previously closed at $164.23.

Analyst upgrades and downgrades

A number of brokerages have commented on JNJ. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday , July 23. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Goldman Sachs Group dropped their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, August 16th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Moderate Buy” and an average price target of $173.21, according to MarketBeat.

Read the latest stock analysis on JNJ

Johnson & Johnson trading rose 1.0%

The company’s 50-day simple moving average is $155.68, and its 200-day simple moving average is $153.51. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44. The firm has a market cap of $399.17 billion, a PE ratio of 10.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. In the same period last year, the company earned $2.80 per share. As a group, sell-side analysts expect that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents an annualized dividend of $4.96 and a yield of 2.99%. The ex-dividend date is Tuesday, August 27. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Hedge funds influence Johnson & Johnson

Several hedge funds and other institutional investors have recently modified their holdings of JNJ. GUNN & Co INVESTMENT MANAGEMENT INC. grew its position in Johnson & Johnson by 1,194.9% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock worth $37,190,000 after acquiring an additional 218,949 shares during the period. Silver Oak Securities Incorporated boosted its position in Johnson & Johnson by 48.7% in the fourth quarter. Silver Oak Securities Incorporated now owns 5,679 shares of the company’s stock valued at $890,000 after purchasing an additional 1,860 shares in the last quarter. Cora Capital Advisors LLC boosted its holdings in Johnson & Johnson by 5.7% in the fourth quarter. Cora Capital Advisors LLC now owns 3,448 shares of the company’s stock worth $540,000 after buying an additional 185 shares during the period. Blue Chip Partners LLC grew its position in Johnson & Johnson by 0.4% during the 4th quarter. Blue Chip Partners LLC now owns 131,279 shares of the company’s stock worth $20,577,000 after buying an additional 541 shares during the period. shares in the last quarter. Finally, Eagle Wealth Strategies LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $348,000. 69.55% of the shares are held by hedge funds and other institutional investors.

About Johnson & Johnson

(Get a free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Read more

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.